IBIO, INC. (IBIO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
30/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseIBIO / S&P -7.89% / 15.20% |
LoseIBIO / S&P IBIO unavailable / 15.00% |
LoseIBIO / S&P -81.03% / 50.40% |
| 2026-Q12/3 |
WinIBIO / S&P -1.55% / -4.33% |
LoseIBIO / S&P IBIO unavailable / 11.30% |
WinIBIO / S&P 83.87% / 27.70% |
| 2025-Q42/3 |
WinIBIO / S&P 132.53% / 2.65% |
LoseIBIO / S&P IBIO unavailable / 9.00% |
WinIBIO / S&P 49.25% / 13.40% |
| 2025-Q31/3 |
WinIBIO / S&P 9.21% / 8.12% |
LoseIBIO / S&P IBIO unavailable / 4.61% |
LoseIBIO / S&P -69.85% / 13.45% |
| 2025-Q20/3 |
LoseIBIO / S&P -81.09% / 10.94% |
LoseIBIO / S&P IBIO unavailable / 4.83% |
LoseIBIO / S&P -80.56% / 10.63% |
| 2025-Q11/3 |
WinIBIO / S&P 64.08% / -4.27% |
LoseIBIO / S&P IBIO unavailable / 4.98% |
LoseIBIO / S&P -93.78% / 10.57% |
| 2024-Q41/3 |
WinIBIO / S&P 10.36% / 2.41% |
LoseIBIO / S&P IBIO unavailable / 5.25% |
LoseIBIO / S&P -95.59% / 6.15% |
| 2024-Q30/3 |
LoseIBIO / S&P 5.21% / 5.89% |
LoseIBIO / S&P IBIO unavailable / 5.89% |
LoseIBIO / S&P -94.18% / 6.11% |
| 2024-Q20/3 |
LoseIBIO / S&P -48.03% / 4.28% |
LoseIBIO / S&P IBIO unavailable / 5.38% |
LoseIBIO / S&P -88.29% / 5.12% |
| 2024-Q11/3 |
WinIBIO / S&P 196.35% / 10.56% |
LoseIBIO / S&P IBIO unavailable / 5.71% |
LoseIBIO / S&P -94.04% / 5.59% |
| 2023-Q40/3 |
LoseIBIO / S&P -77.17% / 11.69% |
LoseIBIO / S&P IBIO unavailable / 6.81% |
LoseIBIO / S&P -79.42% / 7.78% |
| 2023-Q31/3 |
LoseIBIO / S&P -50.82% / -3.27% |
LoseIBIO / S&P IBIO unavailable / 7.52% |
WinIBIO / S&P 1064.85% / -5.03% |
| 2023-Q21/3 |
LoseIBIO / S&P -70.67% / 8.74% |
LoseIBIO / S&P IBIO unavailable / 9.50% |
WinIBIO / S&P 792.18% / -8.57% |
| 2023-Q12/3 |
WinIBIO / S&P 372.73% / 7.50% |
LoseIBIO / S&P -100.00% / 10.77% |
WinIBIO / S&P 779.98% / -15.69% |
| 2022-Q42/3 |
LoseIBIO / S&P -89.65% / 7.56% |
WinIBIO / S&P 34.33% / 11.88% |
WinIBIO / S&P 810.73% / -17.99% |
| 2022-Q30/3 |
LoseIBIO / S&P -34.62% / -4.88% |
LoseIBIO / S&P -11.98% / 13.47% |
LoseIBIO / S&P IBIO unavailable / -1.41% |
| 2022-Q20/3 |
LoseIBIO / S&P -39.53% / -16.10% |
LoseIBIO / S&P -20.54% / 13.71% |
LoseIBIO / S&P IBIO unavailable / 11.04% |
| 2022-Q11/3 |
LoseIBIO / S&P -21.82% / -4.60% |
WinIBIO / S&P 26.33% / 15.97% |
LoseIBIO / S&P IBIO unavailable / 42.23% |
| 2021-Q41/3 |
LoseIBIO / S&P -48.11% / 11.03% |
WinIBIO / S&P 20.18% / 15.00% |
LoseIBIO / S&P IBIO unavailable / 96.40% |
| 2021-Q31/3 |
LoseIBIO / S&P -29.80% / 0.58% |
WinIBIO / S&P 398.78% / 10.77% |
LoseIBIO / S&P IBIO unavailable / 69.42% |
| 2021-Q21/3 |
LoseIBIO / S&P -1.95% / 8.55% |
WinIBIO / S&P 2095.37% / 6.58% |
LoseIBIO / S&P IBIO unavailable / 51.81% |
| 2021-Q12/3 |
WinIBIO / S&P 46.67% / 6.17% |
WinIBIO / S&P 1640.74% / -1.06% |
LoseIBIO / S&P IBIO unavailable / 7.39% |
| 2020-Q41/3 |
LoseIBIO / S&P -48.28% / 12.15% |
WinIBIO / S&P 932.41% / -3.72% |
LoseIBIO / S&P IBIO unavailable / -33.42% |
| 2020-Q31/3 |
LoseIBIO / S&P -8.56% / 8.93% |
WinIBIO / S&P 182.76% / -2.04% |
LoseIBIO / S&P IBIO unavailable / -27.10% |
| 2020-Q22/3 |
WinIBIO / S&P 109.43% / 20.54% |
WinIBIO / S&P 31.71% / -0.46% |
LoseIBIO / S&P IBIO unavailable / -27.11% |
| 2020-Q11/3 |
WinIBIO / S&P 324.00% / -19.60% |
LoseIBIO / S&P -147.58% / 3.47% |
LoseIBIO / S&P IBIO unavailable / -14.75% |
| 2019-Q40/3 |
LoseIBIO / S&P -53.70% / 9.07% |
LoseIBIO / S&P -172.48% / 5.36% |
LoseIBIO / S&P IBIO unavailable / 2.99% |
| 2019-Q30/3 |
LoseIBIO / S&P -23.94% / 1.70% |
LoseIBIO / S&P -539.39% / 5.02% |
LoseIBIO / S&P IBIO unavailable / 0.21% |
| 2019-Q21/3 |
LoseIBIO / S&P -18.39% / 4.30% |
WinIBIO / S&P 86.36% / 6.64% |
LoseIBIO / S&P IBIO unavailable / 8.65% |
| 2019-Q11/3 |
WinIBIO / S&P 16.00% / 13.65% |
LoseIBIO / S&P -145.40% / 8.12% |
LoseIBIO / S&P IBIO unavailable / 14.29% |
| 2018-Q41/3 |
WinIBIO / S&P -11.76% / -13.52% |
LoseIBIO / S&P -132.46% / 9.05% |
LoseIBIO / S&P IBIO unavailable / 18.23% |
| 2018-Q30/3 |
LoseIBIO / S&P -5.56% / 7.71% |
LoseIBIO / S&P -108.66% / 10.21% |
LoseIBIO / S&P IBIO unavailable / 19.06% |
| 2018-Q20/3 |
LoseIBIO / S&P -59.09% / 3.43% |
LoseIBIO / S&P -88.83% / 9.03% |
LoseIBIO / S&P IBIO unavailable / 14.46% |
| 2018-Q11/3 |
WinIBIO / S&P 22.22% / -0.76% |
LoseIBIO / S&P -4.21% / 7.68% |
LoseIBIO / S&P IBIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseIBIO / S&P -43.75% / 6.64% |
LoseIBIO / S&P -46.88% / 7.03% |
LoseIBIO / S&P IBIO unavailable / 13.82% |
| 2017-Q30/3 |
LoseIBIO / S&P -17.95% / 4.48% |
LoseIBIO / S&P -58.72% / 5.68% |
LoseIBIO / S&P IBIO unavailable / 17.57% |
| 2017-Q20/3 |
LoseIBIO / S&P -9.30% / 3.09% |
LoseIBIO / S&P -58.44% / 4.83% |
LoseIBIO / S&P IBIO unavailable / 17.74% |
| 2017-Q11/3 |
WinIBIO / S&P 7.50% / 6.07% |
LoseIBIO / S&P -47.22% / 3.67% |
LoseIBIO / S&P IBIO unavailable / 13.32% |
| 2016-Q40/3 |
LoseIBIO / S&P -27.27% / 3.82% |
LoseIBIO / S&P -9.91% / 2.09% |
LoseIBIO / S&P IBIO unavailable / 7.05% |
| 2016-Q30/3 |
LoseIBIO / S&P -23.61% / 3.85% |
LoseIBIO / S&P -22.57% / 0.20% |
LoseIBIO / S&P IBIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 70.73% | 20.78% |
| Annualized return | 70.73% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.78% | 83.14% |
| Annualized return | -70.62% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.95% | 319.30% |
| Annualized return | -53.64% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |